Ticker: PDSB

PDS Biotechnology Corporation (NASDAQ: PDSB) - quick take PDSB is a clinical‑stage immunotherapy company with no product revenue. Management has raised capital in 2025 (February equity offering and an April Securities Purchase Agreement) and used proceeds to retire prior loan facilities and fund...